129 related articles for article (PubMed ID: 23643963)
1. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma.
Chen M; Li G; Yan J; Lu X; Cui J; Ni Z; Cheng W; Qian G; Zhang J; Tu H
Clin Chim Acta; 2013 Aug; 423():105-11. PubMed ID: 23643963
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
[TBL] [Abstract][Full Text] [Related]
4. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.
Hippo Y; Watanabe K; Watanabe A; Midorikawa Y; Yamamoto S; Ihara S; Tokita S; Iwanari H; Ito Y; Nakano K; Nezu J; Tsunoda H; Yoshino T; Ohizumi I; Tsuchiya M; Ohnishi S; Makuuchi M; Hamakubo T; Kodama T; Aburatani H
Cancer Res; 2004 Apr; 64(7):2418-23. PubMed ID: 15059894
[TBL] [Abstract][Full Text] [Related]
5. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
6. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.
Qiao SS; Cui ZQ; Gong L; Han H; Chen PC; Guo LM; Yu X; Wei YH; Ha SA; Kim JW; Jin ZT; Li S; Peng JR; Leng XS
Hepatogastroenterology; 2011; 58(110-111):1718-24. PubMed ID: 21940340
[TBL] [Abstract][Full Text] [Related]
8. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
10. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma.
Zhang Q; Xiao Q; Lin Z; Ying X; Li Z; Lin JM
Clin Biochem; 2010 Aug; 43(12):1003-8. PubMed ID: 20444424
[TBL] [Abstract][Full Text] [Related]
11. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
Abdelgawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
Asian Pac J Cancer Prev; 2013; 14(12):7345-9. PubMed ID: 24460300
[TBL] [Abstract][Full Text] [Related]
12. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of glypican-3 in human hepatocellular carcinoma.
Suzuki M; Sugimoto K; Tanaka J; Tameda M; Inagaki Y; Kusagawa S; Nojiri K; Beppu T; Yoneda K; Yamamoto N; Ito M; Yoneda M; Uchida K; Takase K; Shiraki K
Anticancer Res; 2010 Dec; 30(12):5055-61. PubMed ID: 21187490
[TBL] [Abstract][Full Text] [Related]
14. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.
Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G
Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222
[TBL] [Abstract][Full Text] [Related]
17. [Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma].
Komori H; Beppu T; Baba H; Nakatsura T; Nishimura Y
Nihon Rinsho; 2010 Jul; 68 Suppl 7():833-6. PubMed ID: 20960882
[No Abstract] [Full Text] [Related]
18. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC.
Wang W; Zhao LJ; Wang Y; Tao QY; Feitelson MA; Zhao P; Ren H; Qi ZT
Cancer Biomark; 2011-2012; 11(1):29-39. PubMed ID: 22820138
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
20. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Jin-no K; Tanimizu M; Hyodo I; Nishikawa Y; Hosokawa Y; Endo H; Doi T; Mandai K; Ishitsuka H
Cancer; 1998 Apr; 82(7):1260-7. PubMed ID: 9529017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]